Oncofertility Consortium

This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages) The topic of this article may not meet Wikipedia's notability guidelines for companies and organizations. Please help to demonstrate the notability of the topic by citing reliable secondary sources that are independent of the topic and provide significant coverage of it beyond a mere trivial mention. If notability cannot be shown, the article is likely to be merged, redirected, or deleted. Find sources: "Oncofertility Consortium" – news · newspapers · books · scholar · JSTOR (November 2012) (Learn how and when to remove this message) This article includes a list of references, related reading, or external links, but its sources remain unclear because it lacks inline citations. Please help improve this article by introducing more precise citations. (November 2012) (Learn how and when to remove this message) This article relies excessively on references to primary sources. Please improve this article by adding secondary or tertiary sources. Find sources: "Oncofertility Consortium" – news · newspapers · books · scholar · JSTOR (November 2012) (Learn how and when to remove this message) (Learn how and when to remove this message)

The Oncofertility Consortium is an international, multi-institutional group that assesses the impact of cancer and its treatment on reproductive health. Founded by Dr. Teresa Woodruff in 2007, its primary mission is to expand fertility options for cancer survivors. It has since expanded this mission to include non-oncologic conditions that affect fertility, including differences of sex development, gender-affirming treatment, and transfusion-dependent thalassemia.

The term oncofertility refers to an interdisciplinary field that bridges oncology, reproduction, and women’s health research for the purpose of exploring and expanding options for the reproductive future of cancer patients. Clinical care for such patients may include fertility preservation prior to medical interventions as well as family planning, complex contraception, and hormonal management across the cancer survivor's lifespan. The term was coined in 2006 by Dr. Woodruff, at the Feinberg School of Medicine (Northwestern University). Woodruff is the Thomas J. Watkins Professor of Obstetrics and Gynecology at Feinberg.